Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Rare disease-focused Cycle Pharmaceuticals Ltd. announced an $8-per-share acquisition bid for Vanda Pharmaceuticals, Inc. on 6 June, roughly two weeks after Vanda revealed it had received and rejected an unsolicited bid from contract manufacturing and packaging company Future Pak that proposed a takeout priced between $7.25 and $7